DDInter840 DDInter740
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Granisetron {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Granisetron {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Granisetron {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Flecainide
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Granisetron {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Granisetron {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is regulated by {v} (Gene) GARS
GARS {u} (Gene) is upregulated by {v} (Compound) Flecainide
Granisetron {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Granisetron {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is regulated by {v} (Gene) PAPD7
PAPD7 {u} (Gene) is downregulated by {v} (Compound) Flecainide
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Granisetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Granisetron (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Flecainide (Compound)
Granisetron (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Flecainide (Compound)
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Granisetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Granisetron (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is regulated by GARS (Gene) and GARS (Gene) is upregulated by Flecainide (Compound)
Granisetron (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)
Granisetron (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is regulated by PAPD7 (Gene) and PAPD7 (Gene) is downregulated by Flecainide (Compound)